Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.52 |
| ▸ | KIF11 | P52732 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221511 | 0.93 | MAPT (0.52) | AURKATPX2ESR2ESR1MAPT | |
| SCHEMBL9589201 | 0.86 | MEN1 (0.64) | AURKATPX2ESR2ESR1MAPT | |
| SCHEMBL4307301 | 0.86 | MEN1 (0.64) | AURKATPX2ESR2ESR1MAPT | |
| SCHEMBL12952736 | 0.85 | AURKA (0.71) | AURKATPX2KIF11AKR1C2AKR1C1 | |
| SCHEMBL1690017 | 0.85 | AURKA (0.71) | AURKATPX2KIF11ESR1AKR1C2 | |
| SCHEMBL21944789 | 0.82 | AURKA (0.67) | AURKATPX2KIF11AKR1C2AKR1C1 | |
| SCHEMBL7938064 | 0.81 | NR1H2 (0.56) | AURKATPX2ESR2ESR1MAPT | |
| SCHEMBL7729335 | 0.81 | GPR84 (0.59) | ESR2ESR1MAPTEPHX2 | |
| SCHEMBL7938063 | 0.81 | ESR1 (0.56) | ESR2ESR1MAPTEPHX2 | |
| SCHEMBL15146260 | 0.81 | MAPT (0.56) | KIF11MAPTEPHX2SCN5AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| CN-108264631-A | Curing agent and the resin combination for having used the curing agent | 协立化学产业株式会社 | 2018-07-10 | — | — | CN | disclosed |
| US-9541690-B2 | Film using polymerizable liquid crystal composition containing peeling preventive agent | JNC CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20140308462-A1 | FILM USING POLYMERIZABLE LIQUID CRYSTAL COMPOSITION CONTAINING PEELING PREVENTIVE AGENT | JNC PETROCHEMICAL CORPORATION (JP) | 2014-10-16 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| CN-1261876-A | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases | ABBOTT LAB (US) | 2000-08-02 | — | — | CN | disclosed |
| EP-1013629-A1 | Preparation process of fluorine subsituted aromatic compound | Mitsui Chemicals, Inc. (JP) | 2000-06-28 | — | — | EP | disclosed |
| EP-1001930-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-0679633-B1 | Diaminobenzene derivatives and polyimides prepared therefrom | NISSAN CHEMICAL IND LTD (JP) | 1999-11-03 | — | — | EP | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5861534-A | CHEMICAL INTERMEDIATES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-01-19 | — | — | US | disclosed |
| US-5665856-A | Diaminobenzene derivatives and polyimides prepared therefrom | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-09 | — | — | US | disclosed |
| EP-0679633-A1 | Diaminobenzene derivatives and polyimides prepared therefrom | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | AURKA 4837/4885TPX2 378/4885ESR2 4547/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | AURKA 4837/4885TPX2 378/4885ESR2 4547/4885 |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | AURKA 1693/4885TPX2 199/4885ESR2 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.